[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastro-intestinal-bleeding\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastro-intestinal-bleeding":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100546356","phase-3-reducing-gastrointestinal-bleeding-with-proton-pump-inhibitor-therapy-in-acute-venous-thromboembolism-100546356",false,"NCT06393868","Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism","Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism: Pilot Randomized Study (RADIANT Study)","Inclusion Criteria:\n\n1. Male or female 65 years or older at the time of enrolment. Enrolment is limited to older adults as age is an important non-modifiable risk factor for bleeding. This will ensure the study population includes participants who may be more likely to benefit from omeprazole (compared to those with no risk factors) because all participants will have at least 1 risk factor for bleeding.\n2. Newly diagnosed VTE which includes VTE at any site such as (but not limited to) DVT of upper or lower limbs, PE, cerebral vein thrombosis, portal vein thrombosis, other splanchnic vein thrombosis.\n3. Planned for 3 months (90 days) or more of therapeutic anticoagulation with any anticoagulant.\n4. Patient or delegate is able and willing to comply with follow-up examinations contained within the consent form.\n\nExclusion Criteria:\n\n1. Therapeutic anticoagulation therapy for more than 7 days\n2. Currently prescribed PPI for regular daily use (patients receiving H2 receptor antagonists will not be excluded),\n3. Previous upper GI bleeding,\n4. Need for dual antiplatelet therapy,\n5. Contraindications to omeprazole (hypersensitivity to omeprazole, or other substituted benzimidazole PPIs, concomitant use with products that contain rilpivirine, significant drug interactions, up to the discretion of the site investigator),\n6. Life expectancy is less than 3 months.","ALL","65 Years",{"count":19,"type":20},360,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The investigators are studying whether treatment with a proton pump inhibitor called omeprazole reduces gastrointestinal bleeding in older adults taking blood thinners for a blood clot (venous thromboembolism). The purpose of this study, a pilot study or a feasibility study, is to test the study plan and determine whether enough participants will join a larger study and accept the study procedures.",[26,27,28],"Venous Thromboembolism","Gastro Intestinal Bleeding","Blood Clot",[30,31,32],"Omeprazole","VTE","GI Bleeding","RECRUITING","2026-01-20",{"date":36,"type":37},"2026-01-22","ACTUAL",{"date":39,"type":37},"2024-11-06",{"date":41,"type":20},"2028-03",{"name":43,"class":44},"Ottawa Hospital Research Institute","OTHER",7,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100602602","gastrointestinal-bleeding-is-blood-loss-in-the-digestive-tract-classified-as-upper-or-lower-ischemic-heart-disease-is-due-to-blocked-heart-arteries-antiplatelet-drugs-help-prevent-heart-attacks-but-increase-gi-bleeding-risk-especially-when-used-together-as-dual-therapy-100602602","NCT07125651","Gastrointestinal Bleeding is Blood Loss in the Digestive Tract, Classified as Upper or Lower. Ischemic Heart Disease is Due to Blocked Heart Arteries. Antiplatelet Drugs Help Prevent Heart Attacks But Increase GI Bleeding Risk, Especially When Used Together as Dual Therapy.","Prevalence of Gastrointestinal Bleeding in Ischemic Heart Disease Patients Undergoing Single Compared to Dual Antiplatelet Treatment","Inclusion Criteria:\n\n* Patients (aged 18 years old and older) who were diagnosed ischemic heart disease on single or dual antiplatelet therapy and developed gastrointestinal bleeding (manifestation of hematemesis, melena or bleeding per rectum).\n\nExclusion Criteria:\n\n* Patients on anticoagulant.\n* Patients with bleeding tendencies.\n* Individuals with other comorbidities.\n* patients with acute coronary syndrome.\n* Uncooperative patients.","18 Years",{"count":55,"type":20},112,"OBSERVATIONAL","Gastrointestinal bleeding is blood loss in the digestive tract, classified as upper or lower. Ischemic heart disease is due to blocked heart arteries. Antiplatelet drugs help prevent heart attacks but increase GI bleeding risk, especially when used together as dual therapy. This study aims to compare the prevalence and risk of gastrointestinal bleeding in ischemic heart disease patients on single versus dual antiplatelet therapy, and to explore strategies for reducing gastrointestinal bleeding in these patients, enhancing treatment safety without compromising cardiovascular protection.",[27,59,60,61],"Ischaemic Heart Diseases","Antiplatelet Drugs","Antiplatelet Drug-related Gastrointestinal Injury",[63,64,65,66,67,68,69],"Gastrointestinal bleeding","GIB","ischemic heart disease","IHD","Antiplatelet therapy","SAPT","DAPT","NOT_YET_RECRUITING","2025-08-10",{"date":73,"type":37},"2025-08-15",{"date":75,"type":20},"2025-09-01",{"date":77,"type":20},"2026-10",{"name":79,"class":44},"Assiut University"]